The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SSKN | -45.85% | -88.36% | -34.96% | -100% |
| S&P | +14.5% | +93.32% | +14.09% | +459% |
STRATA Skin Sciences, Inc. is a medical technology company in Dermatology and Plastic Surgery. It engages in developing, commercializing and marketing products for the treatment of dermatologic conditions. The firm operates through the following segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. The Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. The company was founded by Dina Gutkowicz-Krusin in December 1989 and is headquartered in Horsham, PA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $7.66M | -9.2% |
| Gross Profit | $4.31M | -12.9% |
| Gross Margin | 56.19% | -2.4% |
| Market Cap | $9.55M | -11.3% |
| Market Cap / Employee | $0.09M | 0.0% |
| Employees | 106 | 7.1% |
| Net Income | -$2.49M | -2414.1% |
| EBITDA | -$0.92M | -208.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.97M | -12.5% |
| Accounts Receivable | $4.02M | 1.1% |
| Inventory | 3.2 | 20.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $16.05M | -0.9% |
| Short Term Debt | $0.30M | -3.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -32.83% | -15.3% |
| Return On Invested Capital | -25.85% | -7.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.88M | -864.2% |
| Operating Free Cash Flow | -$1.94M | -428.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.02 | 1.30 | 2.21 | 3.58 | 213.61% |
| Price to Sales | 0.34 | 0.36 | 0.33 | 0.29 | -11.57% |
| Price to Tangible Book Value | -2.87 | -4.02 | -3.63 | -1.97 | -28.35% |
| Enterprise Value to EBITDA | -57.62 | 21.08 | -27.55 | -21.70 | -190.05% |
| Return on Equity | -73.5% | -114.2% | -151.2% | -235.4% | 273.83% |
| Total Debt | $16.48M | $16.44M | $16.40M | $16.35M | -0.95% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
